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Novelty and Impact: Cardiac glycosides are phytoestrogens and their use has been associated 
with increased risk of estrogen sensitive cancers. However, the association between their use 
and risk of breast cancer remains unclear. We investigated the association between cardiac 
glycosides use and the risk of breast cancer by systematically reviewing the published 
literature and performing meta-analyses. This study is the first comprehensive systematic 
review and meta-analysis to investigate the association between cardiac-glycosides use and 
risk of breast cancer.   
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Abstract 
Cardiac glycosides are phytoestrogens and have been linked to the risk of estrogen sensitive 
cancers such as uterus cancer. However, the association between use of cardiac glycosides 
and risk of breast cancer remains unclear. We investigated the association between cardiac 
glycosides use and the risk of breast cancer by systematically reviewing the published 
literature and performing meta-analyses. A comprehensive literature search was performed 
using MEDLINE, EMBASE, Web of Science and SCOPUS to identify all relevant articles 
published up to November 2015.  Risk estimates, and accompanying standard errors, for the 
association between cardiac glycoside use and breast cancer were extracted from identified 
studies. Meta-analysis models were used to calculate a combined hazard ratio (HR), and 95% 
confidence interval (CI), and to investigate heterogeneity between studies. In total, 9 studies 
were identified investigating cardiac glycosides use and risk of developing breast cancer. 
Overall, there was evidence to suggest an association between cardiac glycosides use and 
breast cancer risk (HR=1.34; 95% CI 1.25, 1.44; p<0.001) with little variation in the 
association between studies (I2=16%, p for heterogeneity =0.30). Results were little altered 
when analysis was restricted to studies with high quality scores or cohort studies. Overall, 
there was a 34% increase in breast risk with use of cardiac glycosides but it is unclear 
whether this association reflects confounding or is causal. Further observational studies are 
required to examine this association particularly for estrogen receptor positive breast cancer 
and to explore the role of potential confounding variables. 
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Introduction 
Cardiac glycosides (digoxin and digitalis) are phyto-estrogens 1 and are used to treat heart 
failure and supra-ventricular arrhythmias (atrial fibrillation/flutter) 2. Early animal studies 
indicate that cardiac glycosides may bind to estrogen receptors (ER) and have estrogenic 
effects 1. In support of this, digoxin has been found to induce gynecomastia in men 3,4.   
It has long been recognised that estrogen therapy increases breast cancer risk 5–8, therefore the 
effect of cardiac glycosides on breast cancer risk is of some concern.  Research into the 
association between cardiac glycosides and breast cancer risk began in the 1970s 9. Since 
then numerous additional studies have been conducted. However this research is difficult to 
interpret because of the number of studies conducted, the different sizes and powers of these 
studies and the seemingly conflicting results 10,11. Although an earlier observational study 12, 
conducted a brief meta-analysis for digoxin and breast cancer risk, this meta-analysis only 
searched one bibliographic database (with a literature search which initially identified only 67 
articles), did not report detailed characteristics of the included studies, did not investigate 
study quality and included two overlapping studies 13,14.  
Therefore, the aim of this study was to perform a systematic review using a wide and 
comprehensive search strategy to identify all relevant literature and to conduct a meta-
analysis of the association between cardiac glycosides and breast cancer risk.  
 
Methods 
Search strategy 
Studies were identified by searching four electronic databases; EMBASE (Reed Elsevier 
PLC, Amsterdam, Netherlands), MEDLINE (US National Library of Medicine, National 
Institutes of Health, Bethesda, Maryland, USA), Web of Science (Thomson Reuters, New 
York USA), and SCOPUS (Elsevier B V) from inception to November 2105.   
The literature search was made with no restrictions. The MEDLINE search strategy used the 
following text words or Medical Subject Headings (Mesh): Breast neoplasms, breast, 
neoplasms, cancer, carcinoma, carcinomas, digoxin, digitoxin, cardiac glycosides, cardiac 
glycoside, digitalis, sodium potassium ATPase inhibitors, foxglove, cardiotonic steroid, 
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bufadienolide, bufalin, cardenolide, proscillaridin. The full MEDLINE search is shown in 
Supplementary Table S1. Similar searches were conducted on the other electronic databases.    
Eligibility criteria 
Articles were screened independently by two investigators (RK, and CC). Articles were 
included if they met the following inclusion criteria: they reported a risk estimate (odds ratio 
(OR), hazard ratio (HR), standardised incidence ratio (SIR), or rate ratio (RR)) for the 
association between cardiac glycoside use and breast cancer in women. First, the articles 
retrieved from searches were screened by titles and abstracts and articles were excluded at 
this stage if they were obviously irrelevant. In cases were eligibility could not be determined 
via article abstracts, full text papers were requested and assessed. The reference lists of 
included studies were also hand searched. Finally, using Web of Science articles citing the 
identified studies were also searched to identify any further relevant articles. Finally, 
duplicate articles were excluded.  
Data extraction 
Data was independently extracted from all relevant studies by two investigators (RK, and 
CC) including information on author, year of publication, location, study population, follow-
up in years, exposure ascertainment, type of cardiac glycosides used, classification of cardiac 
glycosides use (ever, never, former, current), outcome ascertainment, outcome reported and 
confounders adjusted for. In addition, studies that have provided results by estrogen receptor 
(ER) status (positive, negative, unknown) were examined. The Newcastle Ottawa Scale 
(NOS) 15 was used to assess study quality with a cut-off of five used to define higher quality 
articles.   
Statistical analysis 
Risk estimates (ORs, HRs, SIRs, or RRs) and accompanying standard errors were extracted 
from each study for the association between cardiac glycoside use and breast cancer risk. In 
each study, the risk estimate (and standard error) that was adjusted for the most potential 
confounders was extracted. If not reported within studies, risk estimates were calculated 
using information provided where possible. Specifically, in a Swedish study no confidence 
intervals (CI) were reported and therefore CIs were calculated from data reported in Table 1 
of the Stenkvist paper 16. Also, in the Friedman study CIs were calculated based upon the 
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observed and expected number of breast cancer cases based upon a Poisson exact confidence 
interval as calculated by STATA 17.  
By necessity, ORs (from two studies), HRs (from 2 studies), RRs (from 3 studies) and SIR 
(from 2 studies) were combined.  However, the OR should approximate a HR and a RR when 
the disease of interest is  not common  18.  As between study heterogeneity was anticipated, 
random effects models were used to produce an overall pooled HR with 95% confidence 
intervals (CI) 19. Heterogeneity among studies was investigated using a Chi-squared test and 
I-squared statistic (I2) 20. Sensitivity analyses were conducted to investigate whether results 
differed on the basis of study design (case–control or nested case–control/cohort) or quality 
score (NOS score of five or more). To check for publication bias, funnel plots were produced 
to investigate evidence for asymmetry. All meta-analyses were conducted in Review 
Manager version 5.1 (Nordic Cochrane Centre, Copenhagen, Denmark). 
 
Results 
Literature search 
The initial database search ascertained 1,171 articles, of which 1,113 were excluded after 
screening of titles and abstracts (Figure 1). The remaining 58 potentially relevant articles 
were screened by full text for inclusion. Duplicate articles (n=37), conference abstracts (n=1) 
and review articles (n=6) were excluded. Additional exclusions included those studies that 
included male breast cancer patients (n=2), and that reported relapse/recurrence (n=2) or 
mortality (n=2) outcomes. A further 2 studies were identified from hand searching the 
reference list of included articles 10,21. Two articles were based upon the one study 13,14 and so 
the later larger study was retained 13.  Therefore 9 studies met the inclusion criteria 10–
13,16,17,21–23.   
Study characteristics 
Characteristics of the included studies are shown in Table 1. There were four case–control 
studies, including two nested case–control studies, and an additional five cohort studies. Four 
studies originated in Europe; one in the UK 11, four in Scandinavia (Denmark, Norway, 
Finland and Sweden) 13,16,21,23. Two were conducted in the USA 10,12 and for one study the 
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origin was not reported 17. Breast cancer cases were ascertained through cancer registries in 
four articles.  
Methods of exposure ascertainment varied across studies (Table 1). Eight of the 9 studies 
solely used medical records, register data, or questionnaire. Only one study used a 
combination of questionnaire and medical records. Digoxin use was investigated in three 
studies, while digitalis was the main exposure in five studies and the remaining study 
investigated digitoxin (Table 2). Quality scores calculated for each study are shown in table 
2. Seven studies had high quality scores (≥5) 11–13,16,21–23. 
All but one of the cohort studies accounted for age in their analyses 10 and all of the case–
control studies matched controls to cases by age. The confounders accounted for in analyses 
varied markedly across studies with some adjusting for few or no confounders whilst others 
adjusted for a wide range of confounders including body mass index (BMI), hormone 
replacement therapy (HRT), and medication use (see Table2).  
Main findings 
Overall there was an increase in rate of breast cancer among cardiac glycosides users 
compared with non-users (HR= 1.34; 95% CI 1.25, 1.44; p<0.00001) with little evidence of 
heterogeneity (I2=16%, p for heterogeneity =0.30) (Figure 2). Funnel plots revealed no 
evidence of asymmetry which would be indicative of publication bias (Supplementary Figure 
S1). 
The association was similar in studies which investigated digoxin (pooled HR= 1.29; 95% CI 
1.11, 1.51; p=0.0009) or studies which investigated digitalis (pooled HR= 1.42; 95% CI 1.23, 
1.63; p<0.00001). Repeating the analysis in higher quality studies (ie. removing two studies 
that scored less than five on the NOS) the main finding was little altered (pooled HR= 1.31; 
95% CI 1.19, 1.44; p<0.00001) and the heterogeneity increased slightly (I2=30%, p for 
heterogeneity= 0.02). When restricting the analysis to cohort studies the estimate was slightly 
more marked (HR=1.39; 95% CI 1.33, 1.46; p<0.00001) with no heterogeneity observed 
(I2=0%, p for heterogeneity= 0.95).  
Only two of the 9 studies investigated estrogen receptor status. Digoxin users appeared to 
have stronger associations with estrogen receptor positive breast cancer (RR = 1.35; 95% CI 
1.26, 1.45 and HR = 1.46; 95% CI 1.10, 1.95) than estrogen receptor negative breast cancer 
(RR = 1.20; 95% CI 1.03, 1.40 and HR = 1.12; 95% CI 0.52, 2.37) respectively 12,13. 
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Discussion 
Our study provides evidence that women using cardiac glycosides have increased breast 
cancer risk by around 35%. This association was fairly consistent across studies and most of 
the inconsistency reflected the magnitude of the increase, as all studies observed increased 
risks of breast cancer in cardiac glycoside users, though in some this increase was small and 
not significant. These findings were little altered when investigating cohort studies or higher 
quality studies.  
The cause of the increased breast cancer risk in women using cardiac glycosides is unclear.  
As with all observational studies, we cannot rule out the effect of confounding. Our meta-
analysis is based upon the adjustment for confounders conducted within each original study 
but these adjustments were not consistent across studies and a number of studies 13,16,17,21–23 
adjusted for few confounders. Only one study used methods based upon restriction 11, that 
have been recommended to reduce the risk of confounding 24. In that study 11, the cohort was 
restricted solely to patients with cardiac glycoside indications (in particular congestive heart 
failure, atrial fibrillation, atrial flutter, and other supra-ventricular tachycardia) and there was 
no association between digoxin and breast cancer risk (OR=1.07; 95% CI 0.90, 1.26). This is 
arguably a better analysis because there are shared risk factors between cardiovascular 
disease and breast cancer which may have less effect on this comparison as digoxin users are 
compared with non-users with similar indications. Alternatively, the association may not 
reflect confounding but could be real. Cardiac glycosides are phyto-estrogens 1 and may have 
estrogenic effects 25,26, although the evidence for this is limited, as noted in a recent IARC 
monograph 27. If real this estrogenic effect of cardiac glycosides could increase breast cancer 
risk similar to increases seen for estrogen hormone therapy 5–8. In support of this, there were 
stronger associations for digoxin users with  estrogen receptor positive breast cancer  
compared with estrogen receptor negative breast cancer 12,13. However, there is a lack of such 
information available and future studies should include ER receptor status of breast cancer 
patients in cardiac glycosides users. Moreover, there is a need for further observational 
studies with comprehensive investigation of methods to adjust for confounding, for instance 
by restricting the population to patients with cardiac glycoside indications, to investigate 
whether the increased risks observed in our meta-analysis are real or reflect confounding. 
Another weakness was that studies reported different measures of association (including ORs, 
HRs, RRs), but by necessity these were combined. However, it is reassuring that despite this 
there was little heterogeneity 18. 
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Our meta-analysis results are similar to the brief meta-analysis conducted by Ahern et al. 
which observed a 37% increase in breast cancer risk with digoxin use 12, but their study 
searched only one database and only included 6 articles, and erroneously included two studies 
which overlapped 13,14. Furthermore, their study did not report in detail characteristics of the 
individual studies (such as confounders), conduct quality scoring, or investigate funnel plots.  
In conclusion; in this systematic review and meta-analysis, women using cardiac glycosides 
had an increased risk of developing breast cancer. However, additional studies are required to 
examine this association particularly for estrogen receptor positive breast cancer and to 
explore whether this increased risk would persist after additional adjustment for potential 
confounding.  
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Table 1. Characteristics of studies of cardiac glycosides use and breast cancer risk 
Author (year), location Design Exposure period 
(years) 
Study population Breast cancer ascertainment Exposure source NOS 
score 
Couraud et al (2014), UK [11] NC-C 22 CPRD (CG related indication) a Medical records Medical records 8 
Ahern et al (2014), US [12] Cohort 16 Nurses’ Health study (PM) Questionnaires & medical records Biennially self-reported questionnaires 7 
Hartz et al (2013), US [10] Cohort 13 Women’s health initiative (PM) Self-administered self-report Self-administered self-report 3 
Biggar et al (2011), Denmark [13] Cohort 13 Danish Prescription Database Danish cancer registry Prescription registry 8 
Haux et al (2001), Norway [21] C-C 10 Norwegian population Norwegian cancer registry Digitoxin lab database 5 
Friedman (1984) [17] Cohort 4 NR NR Computer stored pharmacy records 2 
Danielson (1982), US [22] Cohort 3 Group health cooperative (PM) NR Group health records 5 
Stenkvist (1980), Sweden [16] C-C NR Swedish Population Computerized population register Questionnaire and hospital records 5 
Aromaa et al (1976), Finland [23] C-C NR FCR & SII’s pop.  register (HT) Finnish cancer registry Register for HT prescriptions 5 
Abbreviations: C-C: Case –Control; NC-C: Nested Case-Control; CPRD: Clinical Practice Research Datalink; CG: Cardiac Glycosides; PM: Postmenopausal; NR: Not Reported; FCR: Finnish 
Cancer Registry; SII: Social Insurance Institution; pop: population; HT: Hypertension; NOS: Newcastle-Ottawa Scale. 
a patient with a diagnosis of congestive heart failure, atrial fibrillation or atrial flutter, or supra-ventricular tachycardia 
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Table 2. Summary of included studies of cardiac glycosides use and breast cancer risk 
Author (year), location Comparison 
No. of breast 
cancer 
casesa 
No. of non-
breast cancer 
controlsb 
Risk measurement 
(95% CI) Adjustments 
Couraud et al (2014), UK [11] Digoxin user vs never user 898 
 
52,556 OR=1.07 (0.90, 1.26) (Matched on Age, date of cohort entry, and duration of 
follow-up), smoking, BMI, CG-related indication, HRT, 
estrogen-based contraceptive drug, statins, aspirin, oral 
anticoagulants and anti-platelets, NSAIDs, Anti- 
hypertensive drugs, and anti-diabetic drugs. 
Ahern et al (2014), US [12] Digoxin current user vs. never 
user 
4,576 70,394 HR=1.40 (1.18, 1.65) Age, height, BMI, age (at menarche, menopause, first 
birth and parity), alcohol, postmenopausal hormones 
use, family history, personal history of benign breast 
disease, mammography screening in the past 2 years, 
aspirin, ibuprofen, cholesterol-lowering drugs, and 
tamoxifen. 
Hartz et al (2013), US [10] Digitalis ever user vs. non-user NR NR HR=1.46 (1.24, 1.72) NR 
Biggar et al (2011), Denmark [13] Digoxin current user vs. never 
user 
49,016 2,067,013 RR=1.39 (1.32,1.46) Age, calendar period 
Haux et al (2001), Norway [21] Digitoxin user versus non-user 
(based upon expected breast 
cancer from national cancer rates)  
57 4,969 SIR=1.25 (0.95, 1.62) Matched on age, year of birth 
Friedman (1984) [17] Digitalis ever user vs. expected 
user 
20 143,371 SIR=1.21 (0.74,1.87) Age-sex standardised 
Danielson (1982), US [22] Digitalis glycosides user vs. non-
user 
302 NR RR=1.30 (0.7, 2.2) Age 
Stenkvist (1980), Sweden [16] Digitalis ever user vs. non-user 
 
179 
 
 179 OR=1.39 (0.76, 2.57) Matched on age 
Aromaa et al (1976), Finland [23] Any digitalis ever user vs non-
user   
109 109 RR=1.33 (0.73, 2.48) Matched on age, geographic area, and duration of 
Hypertension treatment 
      
Abbreviations: NR: not reported; BMI: Body Mass Index; CG: Cardiac glycosides; HRT: Hormone Replacement Therapy; ER: Estrogen; NSAIDs: Non-Steroidal Anti-Inflammatory Drugs. 
a Number of cases in study population regardless of medication use. 
b Number of controls in study population regardless of medication use.
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